Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826960 | 0.83 | KDR (0.54) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL7485861 | 0.82 | EGFR (0.66) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL31060666 | 0.81 | EGFR (0.61) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL4400367 | 0.81 | PDGFRB (0.72) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL7487419 | 0.79 | PDGFRB (0.70) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL5221950 | 0.79 | EGFR (0.55) | EGFRPDGFRBPDGFRA | |
| SCHEMBL7481076 | 0.78 | EGFR (0.78) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL17225391 | 0.78 | EGFR (0.56) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL24444526 | 0.78 | SRC (0.66) | EGFRPDGFRBPDGFRAFGFR2 | |
| SCHEMBL31060325 | 0.78 | FGFR2 (0.78) | EGFRPDGFRBPDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219929-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219929-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | EGFR 8/4885PDGFRB 105/4885PDGFRA 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.